Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870831 | 1.00 | CES2 (0.67) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL12019561 | 0.89 | STS (0.59) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL2199255 | 0.87 | CES2 (0.65) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL307622 | 0.86 | CES2 (0.62) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL2540654 | 0.84 | F10 (0.49) | CES2CES1PARP1HSD17B2MEN1 | |
| SCHEMBL15386976 | 0.84 | F10 (0.49) | CES2CES1PARP1HSD17B2MEN1 | |
| SCHEMBL14319078 | 0.83 | CES2 (0.59) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL21425705 | 0.83 | MEN1 (0.60) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL2353790 | 0.83 | CES2 (0.59) | CES2CES1PARP1HSD17B2NPC1 | |
| SCHEMBL15386970 | 0.82 | LMNA (0.56) | CES2CES1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-112041320-B | Compound capable of being used as tumor inhibitor and preparation method and application thereof | 甘李药业股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-0275092-A1 | Process for preparing (+)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1,7-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0041711-B1 | 6-CHLORO- OR 6-BROMO-1,2-DIHYDRO-3H-PYRROLO(1,2-A)-PYRROLE-1-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4458081-A | ANTIINFLAMMATORY, ANALGESIC, ANTICOAGULANT, MUSCLE RELAXANT | SYNTEX (U.S.A.) INC. (US) | 1984-07-03 | — | — | US | disclosed |
| US-4454326-A | 5-Aroyl 6-chloro or 6-bromo 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1,1-di-carboxylates | SYNTEX (U.S.A.) INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4410534-A | 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4347187-A | Process for preparing 5-aroyl 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347186-A | Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein | SYNTEX (U.S.A.) INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4344943-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1982-08-17 | — | — | US | disclosed |
| EP-0041711-A1 | 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo(1,2-a)-pyrrole-1-carboxylic acids and derivatives thereof, process for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-12-16 | — | — | EP | disclosed |
| US-4089969-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, SMOOTH MUSCLE RELAXANT | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | CES2 4326/4885CES1 3922/4885PARP1 457/4885 |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | CES2 3795/4885CES1 3214/4885PARP1 953/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | CES2 3852/4885CES1 3063/4885PARP1 865/4885 |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | CES2 3623/4885CES1 3392/4885PARP1 928/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | CES2 4582/4885CES1 3502/4885PARP1 457/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | CES2 4627/4885CES1 3155/4885PARP1 694/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | CES2 4326/4885CES1 3922/4885PARP1 457/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | CES2 3623/4885CES1 3392/4885PARP1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.